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Abstract
Background: Botulinum neurotoxin (BoNT), the causative agent of botulism, a serious neuroparylatic disease, is produced
by the anaerobic bacterium Clostridium botulinum and consists of a family of seven serotypes (A-H). We previously reported
production of high-affinity monoclonal antibodies to BoNT serotype A.
Methods and Findings: Recombinant peptide fragments of the light chain, the transmembrane and receptor-binding
domains of the heavy chain of botulinum neurotoxin type B (BoNT/B) were expressed in Escherichia coli as GST-fusion
proteins and purified. These proteins were used to immunize BALB/cJ mice for the generation of monoclonal antibodies
(mAbs). Antibody-producing hybridomas were detected using either a direct binding ELISA binding to plate-immobilized
BoNT/B, or with a capture-capture ELISA whereby the capacity of the antibody to capture BoNT/B from solution was tested.
A total of five mAbs were selected, two of which bound the toxin light chain and three bound the receptor-binding domain
of BoNT/B heavy chain. MAb MCS6-27 was identified via capture-capture ELISA and was the only mAb able to bind BoNT/B
in solution under physiological conditions. MAbs F24-1, F26-16, F27-33 and F29-40 were identified via direct binding ELISA,
and were able to capture BoNT/B in solution only in the presence of 0.5–0.9 mM sodium dodecyl sulphate (SDS). MAb
MCS6-27 and an anti-BoNT/B polyclonal antibody were incorporated into a sandwich ELISA that did not require SDS.
Conclusions: We report here the generation of monoclonal antibodies to serotype B and the subsequent development of a
sensitive sandwich immunoassay. This immunoassay has a detection limit of 100 fg BoNT/B, fifty times more sensitive than
the mouse bioassay detection limit of 5 pg BoNT/B. Additionally, this assay detected as little as 39 pg/mL of toxin in skim,
2% and whole milk.
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Introduction
Foodborne botulism is a serious condition in which the patient
experiences a gradual flaccid paralysis, 18 to 36 hours following
consumption of contaminated food. If untreated, botulism can be
fatal. Treatment is a lengthy process that may require hospitalization
for several months with continuous mechanical ventilation [1–2].
Botulinum neurotoxins (BoNTs) are the causative agents of
botulism, and are the most potent naturally-occurring toxins
known [3]. There are seven serotypes of BoNTs, designated A
through G, with serotypes A, B, E and F most frequently
associated with human cases of botulism [4]. BoNT/A is the most
widely studied and best characterized of the BoNT serotypes - a
cursory survey of the scientific literature indicates that there are
approximately three times as many publications about BoNT/A
than the next most frequent serotype, BoNT/B.
In the United States from 2001 to 2007, a total of 139 cases of
foodborne botulism were reported to the Centers for Disease
Control and Prevention (CDC). The majority of these cases were
caused by intoxication by BoNT/A (76 cases) or BoNT/E (46
cases), with only 10 cases directly linked to consumption of food
contaminated with BoNT/B. However, in the same seven years,
BoNT/B was the causative agent of 387 of the 663 cases of infant
botulism (58.4%) recorded by the CDC [5].
Although BoNT/B is a less frequently observed cause of
foodborne botulism, it is nonetheless a significant threat to food
safety. The largest recorded outbreaks of foodborne botulism to
occur in both the United States and United Kingdom (UK) were
attributed to the consumption of food contaminated with
BoNT/B. In April 1977 in Michigan, a total of 59 patients
were diagnosed with type B botulism, caused by eating a sauce
made from improperly home-canned jalapenos. Eleven of the
patients required hospitalization, although there were no
reported deaths [6]. In June 1989 in the UK, 27 patients were
intoxicated (one of whom died) by BoNT/B-contaminated
hazelnut yoghurt [7].
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similar manner. Both toxins are comprised of a 100 kDa heavy
chain (Hc) and a 50 kDa light chain (Lc), linked by a single
disulphide bond. The Hc functions by binding nerve cells and
facilitates the internalization of the Lc, a zinc metalloprotease, into
the pre-synaptic neuron at the neuromuscular junction [8–9]. The
Lc of BoNT/A cleaves synaptosomal-associated protein 25
(SNAP-25) whereas the Lc of BoNT/B cleaves synaptobrevin-2
[10–11]. Either cleavage event prevents the docking of acetylcho-
line-carrying vesicles with the presynaptic membrane, thus
blocking the release of the neurotransmitter into the neuromus-
cular junction and ultimately prohibiting the contraction of the
muscle [9].
We recently reported the development of a sensitive sandwich
ELISA for the detection of BoNT/A, with a detection limit of
2 pg/mL [12]. The mAbs (F1-2, F1-5 and F1-40) that form the
foundation of this sandwich ELISA have been extensively
characterized. Binding of these antibodies to the other serotypes
of BoNT was undetectable [12–14]. Whilst these studies have
allowed the development of a test specific for BoNT/A, it is now
necessary to develop a novel collection of mAbs to facilitate the
development of a sandwich ELISA-based test specific to
BoNT/B.
In this article, we describe the production and basic character-
ization of a collection of monoclonal antibodies specific to BoNT/
B. We also report the development of a new sandwich ELISA,
capable of detecting BoNT/B in buffer at concentrations
undetectable by the mouse bioassay. Finally, we show that this
sandwich ELISA can be used to recover BoNT/B from spiked
milk samples with minimal sample preparation or modification.
Materials and Methods
Recombinant BoNT/B-GST fusion proteins
Commercial enzymes (Phusion High-Fidelity DNA Polymerase,
BamHI, XhoI, T4 polynucleotide kinase [39 phosphatase minus],
T4 DNA ligase [New England BioLabs, Inc., Bethesda, MD])
were used according to the manufacturer’s recommendation.
Primers used were purchased from Integrated DNA Technologies
(Coralville, IA) and are shown in Table 1. Plasmid construction
and manipulation were performed in Escherichia coli TOP10 cells
(Invitrogen, Carlsbad, CA) grown aerobically in Luria-Bertani
(LB) medium at 37uC supplemented with 100 mg/mL ampicillin
[15]. Plasmids or DNA were purified using the QuickClean 5M
range of kits (GenScript Corp., Piscataway, NJ). All automated
DNA sequencing was performed using the Big Dye Terminator
Version 3.1 and XTerminator reagents, and a 3730 DNA
Analyzer (Applied Biosystems, Foster City, CA). The
150,000 Da Botulinum neurotoxin type B holotoxin (BoNT/B)
produced by Clostridium botulinum Strain Okra/Type B1 was used
in our experiments (Metabiologics Inc., Madison, WI).
Total genomic DNA from Clostridium botulinum (Strain Okra/Type
B1), generously provided by Eric Johnson (University of Wisconsin,
Madison WI), was used as a template to amplify the fragments of the
light and heavy chains (Lc, L1, L2, Hc, H1, H2, H3, H4, H5,) using
the primers indicated (see Figure 1 and Table 1). Stop codons (TAA)
were introduced when not present within the genomic DNA of the
cloned region. All subsequent BoNT/B DNA fragments were cloned
into plasmid pCR4-TOPO (Invitrogen) to allow sequencing using
primers M13F and M13R. Additional primers (B-intseqF, B-intseqR)
were required for the longest fragments, Hc and H1. The pCR4-
derived plasmids were then digested using BamHI and XhoI, the
BoNT/B fragment was purified and ligated into BamHI- and XhoI-
digested pGS-21a (Genscript) to yield the correspondently named
pGS plasmid (e.g. pGS-H1 for fragment H1). All pGS-21a-derived
plasmids were sequenced usingprimer pGS-F and pGS-R, toconfirm
the correct integration of the BoNT/A fragment into the vector. The
expression and purification of all GST-fusion proteins was performed
aspreviouslydescribed[13].TherecombinantDNAmethodsusedin
this study were approved by the Institutional Biosafety Committee.
DNA sequences determined in this study have been deposied in
GenBank and accession numbers ore liste3d in Table 2.
Table 1. Primers.
Primer Sequence Constructs
B-LcF GGATCCATGCCAGTTACAATAAATAATTTTAATTATAATG Lc, L1
B-LcR CTCGAGTTATTTAACACTTTTACACATTTGTATCTTATATAC Lc, L2
B-LcintF GGATCCGCAAGTATATTTAATAGACG L2
B-LcintR CTCGAGTTAGCCTTTGTTTTCTTGAAC L1
B-HcF GGATCCGCTCCAGGAATATGTATTGATGTTG Hc,H1,H4
B-HcR CTCGAGTTATTCAGTCCACCCTTCATCTTTAG Hc, H3, H5
B-HcintR1 CTCGAGTTAGCTATTATATTTATTAAACATTTC H1
B-HcintF2 GGATCCGAAATTTTAAATAATATTATCTTAAATTTAAG H2, H5
B-HcintR2 CTCGAGTTAGCTATATGATTGAATTTTATATC H2, H4
B-HcintF3 GGATCCGAATATTTAAAAGATTTTTGGGG H3
M13F GTAAAACGACGGCCAG seq. pCR4 plsamids
M13R CAGGAAACAGCTATGAC seq. pCR4 plasmids
B-intseqF CAATAGATAATGCTTTAACTAAAAGAAATG seq. Hc,H1
B-intseqR GTGTTCTATCTATATCACCATC seq. Hc
pGS-F CAAATTGATAAGTACTTGAAATCC seq. pGS-21a plasmids
pGS-R GCTAGTTATTGCTCAGAGG seq. pGS-21a plasmids
Sites for restriction enzymes BamHI (GGATCC), XhoI (CTCGAG), are shown underlined. Stop codons are shown in bold, in the 39 to 59 (TTA) orientation. The third column
indicates which peptide fragments each primer was used to construct (See Figure 1). Primers used only for sequencing are indicated by the abbreviation ‘‘seq.’’
doi:10.1371/journal.pone.0011047.t001
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The method used for monoclonal antibody production has been
described previously [12]. Significant differences from this method
are described below.
Solutions of three peptide fragments at the concentrations
indicated (Lc, 90 mg/mL; H1, 186 mg/mL; H5, 265 mg/mL) were
mixed with Sigma Adjuvant System #S6322 according to
manufacturer’s instructions (Sigma-Aldrich, St. Louis, MO). Five
female BALB/cJ mice (Simonsen Laboratories, Gilroy, CA) were
immunized three times at 2-week intervals by intraperitoneal
injection (i.p.) of 100 mL of each antigen-adjuvant solution. Two
weeks after the third injection, serum was obtained from each
mouse and evaluated for anti-BoNT/B antibodies via direct
binding ELISA screens. Mice were injected i.p. with 2 mg of the
appropriate peptide fragment in 0.01 M phosphate buffered saline
(PBS; #P-3813, Sigma-Aldrich) three days prior to being
euthanized and cell fusion. Supernatants from cell fusion plates
were subjected to screening either by direct binding ELISA or by a
capture-capture ELISA screen.
The Institutional Animal Care and Use Committee of the
United States Department of Agriculture, Western Regional
Research Center approved the experimental procedures used in
these studies (protocol #’s 04-1-H-05, 09-3). All animal experi-
ments and husbandry involved in the studies presented in this
manuscript were conducted under the guidelines of the U.S.
Government Principles for the Utilization and Care of Vertebrate
Animals Used in Testing, Research and Training.
Screening Methods
Direct binding ELISA screens were performed as previously
described [12], using microtiter plates coated with 50 mL per well
of a 0.1 mg/mL solution of BoNT/B in 0.05 M sodium carbonate
buffer, pH 9.6. Binding was visualized using SuperSignal West
Dura Extended Duration Substrate (Pierce, Rockford, IL)
according to manufacturer’s instructions. The plates were
incubated for 3 min at room temperature and luminescent counts
recorded using a Wallac Victor 2 Multilabel Counter (PerkinEl-
mer Inc., Waltham, MA).
Figure 1. Peptide fragments of BoNT/B light and heavy chains. Diagram is drawn to scale to facilitate size and location comparison between
peptide fragments. The transmembrane (A442 to S858) and receptor-binding (E859 to E1291) domains are indicated [27]. Peptide fragments were
expressed as fusions to GST at the N-terminal. N- and C-terminal amino acids of each peptide fragment are indicated. Fragments used as antigens to
generate monoclonal antibodies in mice are indicated with an asterisk.
doi:10.1371/journal.pone.0011047.g001
Table 2. Characterization of monoclonal antibodies to BoNT/B.
Antibody Screening method Hc isotype Peptides bound* Epitope location
Accession # of Lc and Hc
sequence
F24-1 Direct binding IgG1 Lc, L2 A212 - K441 Lc – GU799549
Hc – GU799550
F24-4 Direct binding IgG1 n/d n/d n/d
F26-16 Direct binding IgA Hc, H3, H5 E1082 - E1291 Lc – GU799551
Hc – GU799552
F27-33 Direct binding IgG1 Lc, L2 A212 - K441 Lc – GU799553
Hc – GU799554
F29-38 Direct binding IgM n/d n/d n/d
F29-40 Direct binding IgG1 Hc, H3, H5 E1082 - E1291 Lc – GU799555
Hc – GU79556
MCS6-27 Capture-capture IgG1 Hc, H5 E859 - E1291 Lc – GU79557
Hc – GU79558
Columns detail the screening procedure used to identify each mAb, the isotype of the Hc of each mAb, the peptides bound, and the epitope location within the
holotoxin deduced from the amino acid sequence of the bound peptides. cDNA sequences of the variable portion of the Lc and Hc of each mAb can be obtained using
the assession numbers indicated.
*=refer to Figure 1 for definition of peptides. n/d=not done.
doi:10.1371/journal.pone.0011047.t002
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Unless stated otherwise, 50 mL per well of all solutions were used.
Microtiter plates were coated with a 1 mg/mL solution of goat
anti-mouse IgG Fc gamma #AP127 (Millipore, Billerica MA) in
0.05 M sodium carbonate buffer, pH 9.6 overnight at 4uC. The
IgG solution was aspirated and non-coated sites blocked by adding
300 mL per well of 3% non-fat dry milk in Tris-buffered saline
containing 0.05% Tween-20 (NFDM-TBST) and the plates were
incubated for 1 h at 37uC. The plates were washed once with
0.05% Tween-20, then cell culture supernatants were added and
the plates were incubated at 37uC for 1 h. The plates were washed
three times with 0.05% Tween-20, then a solution of BoNT/B in
NFDM-TBST (50 ng/mL) was added and the plates were
incubated at 37uC for 1 h. Plates were washed three times as
before, then a 1 mg/mL solution of anti-BoNT/B rabbit
polyclonal antibodies (Metabiologics) in NFDM-TBST was added
and the plates were incubated at 37uC for 1 h. Plates were washed
three times as before, then a 1 mg/mL solution of goat anti-rabbit
HRP-conjugated polyclonal antibodies #A6154 (Sigma-Aldrich)
was added and the plates were incubated at 37uC for 1 h. Plates
were again washed three times, and binding was visualized as
described above.
Cells from the wells giving positive signals for antibody
production were cloned by limiting dilution. Hybridomas were
then expanded and small amounts (usually less than 10 mL) of
ascites fluids obtained (Covance Research Products, Inc., Denver,
PA). Antibodies were purified by affinity chromatography on
Protein-G (for IgG) or Protein L (for IgA) Sepharose. Bound
antibody was eluted with 0.1 M glycine-HCl, pH 2.7 and dialyzed
overnight versus PBS. Protein concentrations were determined
with a BCA-kit (Pierce) using the microplate method suggested by
the manufacturer.
Antibody Isotyping, Western Blotting, Peptide Binding
All coating, blocking and washing steps of subsequent ELISAs
were performed as described for the capture-capture ELISA
screen, unless stated otherwise.
The isotype of each antibody was determined using the SBA
Clonotyping System/HRP in ELISA format, according to
manufacturer’s instructions (Southern Biotech, Birmingham AL).
Western Blotting was performed as previously described [12],
except that BoNT/B was used instead of BoNT/A. BoNT/B was
reduced by the addition of dithiothreitol (DTT) at a final
concentration of 10 mM.
Basic characterization of the epitopes of each antibody was
performed by direct binding ELISA. The wells of clear microtiter
plates were coated with each of the BoNT/B GST-fusion proteins
(see Figure 1), incubated overnight at 4uC, blocked with NFDM-
TBST and washed. Hybridoma supernatant, diluted 1:10 in
NFDM-TBST, was added to each well and incubated for 1 h at
37uC. The plate was washed, then a 1 mg/mL solution of goat
anti-mouse HRP-conjugated polyclonal antibodies #A4416 (Sig-
ma-Aldrich) was added and the plates were incubated at 37uC for
1 h. Plates were again washed three times, then K-Blue substrate
(Neogen Corporation, Lexington, KY) was added (100 mL per
well) and incubated with agitation for 5 min at room temperature.
Stop solution (Neogen) was added (100 mL per well), and
absorbance at 650 nm was measured using a VersaMax micro-
plate reader (Molecular Devices, Sunnyvale CA). Each antibody
was tested in triplicate.
Binding of antibodies to BoNT serotypes A through G
Black microtiter plates were coated with the different serotypes
of BoNT, A through G (Metabiologics) for direct binding ELISA
analysis as described above. Purified anti-BoNT/B monoclonal
antibody at a concentration of 10 mg/mL in NFDM-TBST was
added to each BoNT serotype, and incubated for 1 h at 37uC. The
plates were washed, then a 1 mg/mL solution of goat anti-mouse
HRP-conjugated polyclonal antibodies #A4416 (Sigma-Aldrich)
was added and the plates were incubated at 37uC for 1 h. Plates
were again washed three times, and binding was visualized using
SuperSignal West Dura Extended Duration Substrate as described
above. Each antibody was assayed against each serotype in
triplicate.
Effects of pH and SDS on capture of BoNT/B from
solution by mAbs
Black microtiter plates were coated with the anti-BoNT/B
monoclonal antibodies at 10 mg/mL in 0.05 M sodium carbonate
buffer, pH 9.6 overnight at 4uC. Non-coated sites were blocked
by adding 300 mL per well of 3% non-fat dry milk in Tris
buffered saline containing 0.05% Tween-20. Following incuba-
tion for 1 h at 37uC, plates were washed three times to remove
any residual blocking agent. Solutions of BoNT/B in buffers of
various pH and sodium dodecyl sulphate (SDS) concentrations
were prepared on a deep-well (2 mL) 96-well plate. Phosphate-
buffered saline was added to rows A through G to give a final pH
(60.1) of 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5 and 9.0, respectively. SDS
was added to columns 1 through 12 to give final concentrations of
0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0 mM,
respectively. The final concentration of BoNT/B was 100 ng/mL
in all wells. The deep-well plate was gently agitated to mix the
solutions, then 100 mL of each BoNT/B solution was pipetted
into the corresponding well on the black microtiter plates.
Following incubation for 1 h at 37uC, plates were subsequently
treated in an identical manner to the capture-capture ELISA
described earlier, using the anti-BoNT/B rabbit polyclonal
antibodies, goat anti-rabbit HRP-conjugated polyclonal antibod-
ies and SuperSignal West Dura Extended Duration Substrate to
allow detection of BoNT/B capture. Each antibody was assayed
in triplicate.
In vivo neutralization of BoNT/B
Random groups of 10 mice (4–5 week old female Swiss
Webster mice, 19–21 g; Charles River Laboratories, Portland
MI) were injected intravenously (i.v.) into the lateral tail vein with
100 mL of mAbs diluted in PBS to a final dosage of 80 mg mAbs/
mouse one hour prior to administration with 100 mLo fB o N T / B
containing 460 pg (100 mouse iv LD50 units) diluted in phosphate
gelatin buffer. Control mice were treated with 100 mLo fP B S
instead of mAbs. Mice were monitored closely over a 14-day
period for any symptoms of intoxication, or death. Animal-use
protocols were approved by the Animal Care and Use
Committee of the USDA, Western Regional Research Center,
Albany, CA.
Cloning and sequencing of monoclonal antibodies
mRNA coding for the anti-BoNT/B monoclonal antibodies
was extracted and purified from hybridoma cells as previously
described [13]. mRNA was converted to cDNA, and the heavy
and light chains of each antibody were amplified by PCR as
previously described [16]. The PCR products were gel-purified
and treated with polynucleotide kinase (New England BioLabs).
Circularized vector pCR2.1 (Invitrogen) was digested with
EcoRV and treated with calf intestinal phosphatase (New
England BioLabs). The PCR products were ligated into vector
pCR2.1, transformed into TOP10 cells, then grown and
Botulinum Monoclonal Antibody
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described earlier.
Sandwich ELISA
All combinations of mAbs F24-1, F26-16, F27-33, F29-40,
MCS6-27 and the anti-BoNT/B rabbit polyclonal antibody were
evaluated as capture and detector pairs for the development of a
sandwich assay for BoNT/B detection. Detector mAbs (except the
anti-BoNT/B rabbit polyclonal) were biotinylated using the EZ-
Link Micro-Sulfo-NHS-Lc Biotinylation Kit (Thermo Scientific,
Rockford IL), and then detected using Zymax streptavidin-HRP
conjugate (Zymed, San Francisco, CA). The anti-BoNT/B rabbit
polyclonal binding was detected using goat anti-rabbit HRP-
conjugated polyclonal described earlier (Sigma).
Two pairs of antibodies were identified: F24-1 (capture) and
F29-40 (detector); and MCS6-27 (capture) and the anti-BoNT/B
rabbit polyclonal (detector). Binding conditions and solutions were
optimized (data not shown) to yield the protocols described below.
Unless stated otherwise, all solution volumes were 100 mL per well,
all incubations were performed for 1 h at 37uC with gentle
agitation, and all washes were performed twelve times in water
plus 0.05% Tween.
White microtiter plates were coated with mAbs F24-1 or
MCS6-27 at a concentration of 5 mg/mL in 0.05 M sodium
carbonate buffer, pH 9.6 overnight at 4uC. Non-coated sites
were blocked by adding 300 mL per well of 5% non-fat dry milk
in Tris buffered saline (pH 8.0) containing 0.05% Tween-20
(NFDM-TBST). Plates were incubated and washed as described
above. BoNT/B was added to each plate at concentrations from
5000 to 0 pg/mL in a two-fold dilution series, in TBS pH 6.0
containing 0.6 mM sodium dodecyl sulphate (SDS) for the F24-
1-coated plate, or in NFDM-TBST for the MCS6-27-coated
plate. Plates were incubated and washed. Biotinylated mAb
F29-40 was added to the F24-1-coated plate at a concentration
of 5 mg/mL in TBS, pH 8.0 containing 0.6 mM SDS. The anti-
BoNT/B rabbit polyclonal detector was diluted 2000-fold in
NFDM-TBST and added to the MCS6-27-coated plate. Plates
were incubated and washed. Zymax streptavidin-HRP conju-
gate was diluted 10,000-fold in TBS, pH 8.0 containing 0.6 mM
SDS and added to the F24-1-coated plate. Next, goat anti-rabbit
HRP-conjugated polyclonal antibody was diluted 2000-fold in
NFDM-TBST and added to the MCS6-27-coated plate. Plates
were incubated, washed then binding was visualized as
described earlier.
Detection of BoNT/B in milk matrices
The sandwich assay using MCS6-27 (capture) and the anti-
BoNT/B rabbit polyclonal (detector) was evaluated for its ability
to detect BoNT/B in milk. The sandwich ELISA was performed
as described above, with the exception of the capture stage which
was performed as follows.
Three milk types (skim, 2% fat and whole) were spiked with
BoNT/B at final concentrations of 10000, 5000, 2500, 1250, 625,
312, 156, 78 and 39 pg/mL. Several sample treatments were
evaluated in order to defat the samples. Spiked milk samples were
centrifuged at 14,0006g for 15 min at 6uC. Other samples were
simply diluted in two-fold serial dilutions in blocking buffer [12].
Following defatting or serial dilution, 100 mL of sample was loaded
onto the MCS6-27-coated microtiter plate and incubated for 1 h
at 37uC with gentle agitation. Recovery of BoNT/B from spiked
milk samples is reported as a percentage of the recovery by
comparison to a standard curve of BoNT/B spiked into NFDM-
TBST. Milk samples were analyzed in triplicate.
Results
Characterization of anti-BoNT/B monoclonal antibodies
A total of seven monoclonal antibodies (mAbs) were identified,
cloned and characterized (Table 2). Six mAbs (F24-1, F24-4, F26-
16, F27-33, F29-38, and F29-40) were identified using a
traditional, direct binding ELISA screening method, and a single
mAb (MCS6-27) was identified using the capture-capture screen.
Isotype analysis revealed that mAb F26-16 was an IgA, F29-38
was an IgM, and the remaining five mAbs were all IgG1s. All of
the mAbs possessed kappa light chains.
Sequence analysis of the cloned cDNA coding for the heavy
chain variable region and the light chains of each antibody
revealed that mAbs F24-1 and F24-4 have identical sequences,
and most likely represent independent fusions of a clonally-
expanded population of lymphocytes. The remaining five mAbs
possess unique variable region sequences for their heavy and light
chains, which can be accessed online via the Nucleotide Accession
Numbers shown in Table 2. The leader sequences, framework
regions, complementarity determining regions (CDRs) and J-
regions were identified by inspecting the alignment of the genes for
the mAb heavy and light chains to those of other antibody
sequences [13–14,17–19]. MAbs F24-4 and F29-38 were not used
in any further studies.
Each antibody was studied in Western blot experiments,
probing reduced and unreduced 150 kDa BoNT/B holotoxin
following separation by SDS-PAGE (Figure 2). In this experiment,
a constant amount (mg) of each mAb was used to probe the
Western blot. Exposure times of Western blots varied; mAbs F24-
1, F26-16, F27-33 and F29-40 were exposed for 20 min, whereas
the exposure time for MCS6-27 was 120 min. All of the mAbs
bound the 150 kDa BoNT/B holotoxin in the unreduced samples.
Using reduced samples, mAbs F24-1 and F27-33 bound the
BoNT/B Lc, and mAbs F26-16, F29-40 and MCS6-27 bound the
BoNT/B Hc. Binding to residual 150 kDa BoNT/B holotoxin was
also observed in the reduced samples.
In an effort to more precisely define the binding epitopes for
these mAbs, direct binding ELISA experiments were performed to
identify which BoNT/B GST-fusion peptides each antibody
bound (See Figure 1 and Table 2, columns 4 & 5). MAbs F24-1
Figure 2. Antibody binding on Western blots of reduced and
nonreduced BoNT/B. BoNT/B was separated on 10% SDS-PAGE in the
presence (+)a n da b s e n c e( 2) of 10 mM DTT, transferred to
nitrocellulose membranes and probed with mAbs F24-1, F26-16, F27-
33, F29-40 and MCS6-27. Bands showing the intact holotoxin (Holo.),
heavy chain (Hc) and light chain (Lc) are indicated. Protein relative
molecular weight (rMW) is indicated in kDa.
doi:10.1371/journal.pone.0011047.g002
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not the L1 fragment or any of the other fragments derived from
the BoNT/B heavy chain. The binding epitope for both mAbs is
therefore localized to a 230 amino acid fragment of the BoNT/B
light chain, between amino acids A212 and K441. MAbs F26-16
and F29-40 bound the Hc, H3 and H5 fragments, but not the Lc,
L1, L2, H1, H2 or H4 fragments. The binding epitope for both
mAbs is therefore localized to a 210 amino acid fragment of the
BoNT/B heavy chain, between amino acids E1082 and E1291. In
contrast, mAb MCS6-27 bound fragments Hc and H5, but no
binding to any other fragment was detected, indicating that the
binding epitope is localized to a 433 amino acid fragment of the
BoNT/B heavy chain, between amino acids E859 and E1291.
These observations are consistent with the binding data obtained
from the Western blot experiments described earlier.
Direct binding ELISAs were performed to test whether each
mAb would bind uniquely to BoNT/B, or whether binding to
other BoNT serotypes could be detected. These data are
summarized in Figure 3. MAbs F26-16, F27-33, F29-40 and
MCS6-27 bound only BoNT serotype B, whereas mAb F24-1
bound BoNT serotype B and serotype G.
Effects of pH and SDS on capture of BoNT/B in solution
by mAbs
The ability of each mAb to capture BoNT/B from solution was
evaluated by sandwich ELISA. Plates were coated with the capture
antibody, BoNT/B was applied (100 ng/mL in 16 TBS), and
capture toxin was then detected using a rabbit anti-BoNT/B
polyclonal antibody followed by an HRP-conjugated, goat anti-
rabbit polyclonal antibody (see methods). Initial experiments
indicated that only mAb MCS6-27 was able to capture BoNT/B
from solution. BoNT/B was not detected using mAbs F24-1, F26-
16, F27-33 or F29-40 as capture antibodies (data not shown). The
effects of the pH and SDS concentration of the capture buffer were
then evaluated for all 5 mAbs.
The effect of pH, ranging from 5.5 to 9.0, on the ability of the
mAbs to capture BoNT/B from solution is summarized in Figure 4A.
For the Hc-binding mAbs F26-16, F29-40 and MCS6-27, the pH
optimum for BoNT/B capture spanned a broad range from pH 6.0
to 8.5. For the Lc-binding mAbs F24-1 and F27-33, the pH optimum
for BoNT/B capture was pH 6.0. It should be noted that in the
absence of SDS, no BoNT/B captured by mAbs F24-1, F26-16, F27-
33 and F29-40 was detected at any pH tested.
Figure 4B shows the effect of SDS concentration, ranging from
0 to 2.0 mM, on the capture of BoNT/B at the optimal pH for
each mAb. MCS6-27 captured BoNT/B at SDS concentrations of
0 to 0.4 mM, reaching an optimal point at 0.4 mM SDS then
sharply decreasing such that at SDS concentrations higher than
0.6 mM, BoNT/B capture was not detected. Conversely, no
BoNT/B captured by mAbs F24-1, F26-16, F27-33 and F29-40
was detected at 0 mM SDS, but captured BoNT/B was detected
with increasing concentration of SDS up to approximately
0.5 mM. Each of these mAbs exhibited the greatest amount of
BoNT/B captured at an SDS concentration between 0.5 and
0.8 mM. At SDS concentrations greater than 0.8 mM, the
amount of BoNT/B captured declined sharply, with no captured
BoNT/B detectable at SDS concentrations of 2 mM (not shown).
In vivo neutralization of BoNT/B
mAbs, F24-1, F26-16, F27-33, F29-40 and MCS6-27 were
tested individually for their ability to neutralize BoNT/B holotoxin
in a systemic mouse model of intoxication. One hour following
intravenous (iv) administration of a mAb against BoNT/B, a lethal
dose of BoNT/B (460 pg/mouse or about 100 mouse iv LD50) was
delivered iv and the animals monitored over time. In the absence
of mAbs, intoxicated mice treated with PBS alone died within 3.5–
Figure 3. Antibody binding to BoNT serotypes by direct binding ELISA. Antibody binding to black microtiter plates coated with 0.1 mg/mL
solutions of BoNT serotypes A through G was measured. Data are presented as average of 3 samples 61 standard error.
doi:10.1371/journal.pone.0011047.g003
Botulinum Monoclonal Antibody
PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e110475.5 hrs. Mice pre-treated with 80 mg of F24-1, F26-16, F27-33 or
F29-40 were not protected from death and had survival times similar
to the PBS treated control mice. In contrast, pre-treatment with
80 mg of MCS6-27 completely protected mice from death as well as
any visible symptoms of botulism over the course of 14 days.
Sandwich ELISA for BoNT/B detection
All combinations of mAbs F24-1, F26-16, F27-33, F29-40,
MCS6-27 and the anti-BoNT/B rabbit polyclonal were evaluated
as capture and detector pairs for the development of a sandwich
assay for BoNT/B detection. The combination of MCS6-27
(capture) and the rabbit anti-BoNT/B polyclonal (detector) was
found to be most sensitive, as shown in Figure 5. This ELISA
exhibits a limit of detection (L.O.D., defined as 3 standard
deviations above the zero) of approximately 1 pg/mL BoNT/B,
and a limit of quantitation (L.O.Q., defined as 5 standard
deviations above the zero) of approximately 2 pg/mL BoNT/B. A
correlation coefficient (R) value of 0.98 indicates that the
regression line is an excellent fit.
Detection of BoNT/B in milk matrices
The sandwich ELISA described above was used to measure
BoNT/B toxin recovery from spiked milk samples (skim, 2% and
whole milk). Although several strategies to defat the milk prior to
the ELISA were evaluated, it was found that no defatting or
dilution process was required for any of the milk types. Recovery
of BoNT/B from the spiked milk samples is reported in Table 3.
Toxin recovery ranged from 80.4% to 106.7% at BoNT/B spike
concentrations from 39 to 20,000 pg/mL.
Discussion
We have previously used recombinant GST-fusion peptides of
BoNT/A for the successful identification of the epitope sites of
mAbs F1-2, F1-5 and F1-40, high affinity mAbs that bind BoNT/
A. These studies demonstrated that recombinant peptides of
BoNT/A could be successfully employed as surrogates for the
BoNT/A holotoxin [13–14]. Based upon this observation, we
produced three recombinant GST-BoNT/B fusion peptides (Lc,
H1, H5) for immunizing mice in order to produce mAbs that bind
wild type, intact BoNT/B. It was reasoned that the fusion peptides
would not be toxic to the mice, and also would allow the
production and identification of mAbs that bind specifically to the
light chain (Lc), to the transmembrane domain (H1) and to the
receptor-binding domain (H5) of BoNT/B (see Figure 1). This
rationale was confirmed by the results reported in this paper.
We identified two mAbs that bound BoNT/B Lc (F24-1 and
F27-33) and three mAbs that bound the receptor-binding domain
of the Hc (F26-16, F29-40 and MCS6-27). No mAbs that bound
the transmembrane domain of Hc were identified. The Hc of mAb
F26-16 was found to be an IgA isotype, whereas the Hc of the
other four mAbs were IgG isotypes. All five mAbs exhibited kappa
light chains.
Binding of each mAb to the collection of BoNT/B GST-fusion
peptides shown in Figure 1 was investigated by direct-binding
ELISA. Each purified mAb bound the GST-fusion peptide used as
an antigen to produce it, but not to any other GST-fusion peptide
of BoNT/B. By using smaller GST-fusion peptides, the epitope
location for each mAb could be localized to several hundred
amino acids.
Both mAbs F24-1 and F27-33 bound the Lc of BoNT/B
between residues A212 and K441. MAbs F26-16 and F1-40 bound
the receptor-binding domain of the Hc, between E1082 and
E1291. The epitope of mAb MCS6-27 could not be further
defined because it failed to bind either smaller sub-peptides (H2,
H3) of the receptor-binding domain (H5). Since peptides H2 and
H3 divide the receptor-binding domain, we speculated that mAb
MCS6-27 might bind a region spanning between these two
peptides. To test this hypothesis, we constructed a small synthetic
peptide 20-mer (EERYKIQSYSEYLKDFWGNP) corresponding
to the amino acid sequence spanning peptides H2 and H3.
However, no binding to this peptide was observed (data not
shown). It is possible that MCS6-27 binds a discontinous
conformational epitope that is not entirely present on peptides
H2 or H3, or the short synthetic peptide tested. It can only be
concluded that the epitope for MCS6-27 lies between amino acids
E859 and E1291 of BoNT/B.
The binding of the five mAbs to the BoNT/B holotoxin was
confirmed by Western blot analysis. All five mAbs bound the intact
BoNT/B holotoxin, with F24-1 and F27-33 selectively binding the
Lc of reduced BoNT/B, and F26-16, F29-40 and MCS6-27
binding the Hc of reduced BoNT/B. In order to visualize binding
of MCS6-27 to the nitrocellulose-immobilized BoNT/B, the
exposure time was increased to two hours, six times greater than
that required for the other mAbs. This observation suggests that
MCS6-27 binds poorly to the BoNT/B under these conditions,
possibly because nitrocellulose-immobilized BoNT/B is in a
Figure 4. Effects of SDS concentration and pH on BoNT/B
capture. Plates were coated with the capture antibody: F24-1 X; F26-
16 &; F27-33 m; F29-40 %; MCS6-27N. A. pH of capture buffer (16TBS)
was adjusted for each capture antibody at concentrations of SDS as
follows; F24-1, 0.7 mM; F26-16, 0.5 mM; F27-33, 0.6 mM; F29-40,
0.6 mM; MCS6-27, 0.3 mM. B. Concentration of SDS in capture buffer
was adjusted for each capture antibody at the following pH; F24-1,
pH 6.0; F26-16, pH 7.5; F27-33, pH 6.0; F29-40, pH 8.0; MCS6-27, pH 8.0.
Data are presented as average of 3 samples 61 standard error.
doi:10.1371/journal.pone.0011047.g004
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MCS6-27.
All of the mAbs except F24-1 bound only to BoNT/B. In
contrast, mAb F24-1 bound to plate-immobilized BoNT/G at
approximately 20% the intensity of binding to BoNT/B (Figure 4).
A comparison between the BoNT/B Lc between A212 and K441,
and the corresponding region of the Lc of BoNT/G [20] revealed
64% identity and 92% similarity in the amino acid sequence,
suggesting that some identical or similar residues that comprise the
epitope in BoNT/B are also present in BoNT/G.
The mAbs identified via the two different screening strategies
displayed markedly different properties. None of the mAbs
identified via the traditional direct-binding ELISA were able to
capture BoNT/B from solution in the absence of SDS.
Conversely, MCS6-27, the only mAb identified via the capture-
capture ELISA, was found to be an excellent capture antibody in
the absence of SDS. Furthermore, a prophylactic, intravenous (iv)
injection of 80 mg of mAb MCS6-27 per mouse protected 100% of
the mice studied from death or any symptoms of intoxication from
an iv injection of 460 pg (100 mouse iv LD50) of BoNT/B,
consistent with the observation that mAb MCS6-27 could bind
BoNT/B in vitro under physiological conditions. The ratio of
antibody to LD50 units of BoNT/B toxin neutralized was
approximately 0.8 mg mAb per 1 LD50 unit. A study into the
neutralization of BoNT/A in mice using mAb F1-2 revealed a
ratio of 0.14 mg F1-2 per 1 LD50 unit of BoNT/A [21]. It is
possible that a lower quantity of mAb MCS6-27 is sufficient to
neutralize 1 LD50 unit of BoNT/B, and is the subject of future
studies. We hypothesize that since mAbs F24-1, F26-16, F27-33
and F29-40 were unable to bind BoNT/B in physiological buffer,
they did not bind toxin in vivo and thus failed to protect mice from
the neurotoxic effects of BoNT/B. The ability of a mAb to capture
antigen from solution appears to be an indicator for toxin
neutralization potential. Our data suggest that a capture-capture
screen would be more appropriate than a direct binding ELISA if
mAbs that neutralize toxin are to be identified.
The observation that all of the mAbs isolated using the direct
binding ELISA screen gave strong ELISA titration curves but
failed to bind toxin from solution suggested to us that
immobilization of toxin on the microtiter plates results in an
alteration of some physicochemical properties (e.g., surface charge
or tertiary structure) so that a cryptic epitope is exposed that is not
Figure 5. Sandwich ELISA for detection of BoNT/B. MAb MCS6-27 was used as capture antibody, rabbit anti-BoNT/B polyclonal (Metabiologics)
was used in conjunction with an HRP-conjugated, goat anti-rabbit polyclonal antibody as detector. Data are presented 61 standard error, n=3.
Horizontal dashed lines represent the limit of detection (L.O.D., zero toxin plus 3 standard deviations) and the limit of quantitation (L.O.Q., zero toxin
plus 5 standard deviations).
doi:10.1371/journal.pone.0011047.g005
Table 3. Percentage recovery of BoNT/B from milk as determined by sandwich ELISA.
Spike level (pg/mL)
20000 5000 1250 313 156 78 39
Skim milk 98.565.7 108.464.7 92.362.6 100.566.9 103.263.6 94.168.5 101.8613.7
2% milk 106.263.5 102.463.7 101.762.0 85.762.1 106.760.3 86.561.6 80.4612.1
Whole milk 100.963.7 94.062.2 99.264.5 97.063.6 100.665.3 84.964.6 82.5610.3
Data are presented as averages of three independent experiments, 61 standard error.
doi:10.1371/journal.pone.0011047.t003
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conditions. If such a hypothesis is correct, mAb MCS 6-27 (which
captured toxin in solution and protected from toxin exposure in
vivo) must bind a surface epitope not altered by immobilization in
the wells of the microtiter plate. In an effort to clarify this
possibility, we investigated the effects of two factors, the pH and
SDS concentration of the capture buffer, on the ability of all five
mAbs to capture BoNT/B from solution. The effect of altering the
pH was less marked than that of SDS, although both Lc-binding
mAbs (F24-1, F27-33) displayed a greater sensitivity to alkaline pH
than the other three Hc-binding mAbs (F26-16, F29-40 and
MCS6-27). It is possible that the increasingly basic conditions
greater than pH 6.0 affected the mAb or the toxin Lc in a manner
that caused decreased binding. The same pH conditions did not
affect the toxin Hc, or Hc-binding mAbs, in a way that decreased
binding. However, in the absence of experiments that assay the
structure of both antibody and toxin at each pH, this eventuality
cannot be determined.
The concentration of SDS in the capture buffer had a dramatic
effect on the ability of the mAbs to bind toxin in solution. SDS is
often used at concentrations of 0.1% (,3.5 mM) in acrylamide
gels and associated buffers to bind proteins and cause major
conformational changes, commonly known as denaturation.
However, there exists a dynamic range of SDS concentration at
which SDS binds the protein and induces conformational
changes that do not completely denature the protein. At lower
concentrations, SDS monomers bind to certain high energy sites
on the protein. As the concentration of SDS increases, SDS
monomers bind in a cooperative manner ultimately resulting in
the saturation of binding. [22–23]. It has been shown that the
minimum concentration at which SDS can affect protein
conformation is 0.1 mM, whereas some proteins can become
100% denatured at SDS concentrations of 1 mM [24–25]. Thus,
the effects of SDS concentrations up to 1 mM on antibody
capture were investigated.
Over the range of SDS concentrations investigated, the capture
mAbs separated into two distinct groups, again mirroring the
screen by which each mAb was identified. MAb MCS6-27
captured BoNT/B at SDS concentrations between 0 and 0.4 mM,
whereas the other four mAbs optimally captured toxin at SDS
concentrations between 0.5 and 0.9 mM. A boundary between the
two mAb populations fell at 0.4–0.5 mM SDS. We hypothesize
that across the range of SDS concentrations from 0 to 1.0 mM, the
SDS altered the protein conformation of either BoNT/B or the
capture mAb in a manner that facilitated or inhibited binding. It is
unlikely that either BoNT/B or MCS6-27 were completely
denatured at 0.5 mM SDS, as the concentration of SDS seems
too low to have that effect. However it is possible that the
conformation of one or both proteins was altered sufficiently, or
that key high energy sites on one or both proteins were blocked by
monomeric SDS, resulting in the abolition of binding.
More intriguing is how the role of the SDS might relate to the
screening methods, specifically to the direct binding ELISA. The
surface of the wells on the microtiter plates is described by the
manufacturer as ‘‘a modified, highly charged polystyrene surface
with high affinity to molecules with polar or hydrophilic groups’’
(Maxisorp, Thermo Fisher Scientific, Rochester, NY). SDS is an
anionic molecule, with a ‘tail’ of 12 carbon molecules. It is possible
that the SDS and the microtiter plate surface cause similar
conformational changes in BoNT/B, thus facilitating the binding
of mAbs F24-1, F26-16, F27-33 and F29-40 to BoNT/B in
solution or immobilized on the microtiter plate, respectively. We
are currently investigating the mechanism by which SDS facilitates
binding of these mAbs to BoNT/B in solution.
Our results demonstrate the fundamental importance of using a
screening protocol that most closely mimics the format in which
the antibody will ultimately be used. Although the capture-capture
screen is more time-consuming, costly, and produced fewer
antibodies, it is critical for identification of antibodies to be used
in sandwich ELISA formats, and possibly for antibodies that can
neutralize toxin in vivo.
MAbs F24-1, F26-16, F27-33, F29-40, MCS6-27 and the anti-
BoNT/B rabbit polyclonal were used in all combinations to
identify capture and detector pairs for the development of a
sandwich ELISA for BoNT/B detection. Using mAb F24-1 for
capture and biotinylated F29-40 for detection, an SDS-dependent
sandwich ELISA was constructed. However, the L.O.D. for this
assay was approximately 90 pg/mL BoNT/B, almost two orders
of magnitude higher than the L.O.D. of 1 pg/mL observed for the
most sensitive sandwich ELISA that, under physiological condi-
tions, used mAb MCS6-27 for capture and the anti-BoNT/B
rabbit polyclonal for detection. The L.O.Q. was determined to be
approximately 2 pg/mL. Since 100 uL of sample is evaluated in
the sandwich ELISA described here, the L.O.D. by mass of
BoNT/B was 100 fg. The mouse LD50 of the BoNT/B
preparations used in our laboratory, when injected interperitone-
ally was found to be 5 pg per mouse (Cheng, unpublished data).
Our sandwich ELISA is therefore approximately 50-fold more
sensitive than the mouse bioassay for the detection of BoNT/B.
We have previously described the development and application
of a sandwich ELISA for the detection of BoNT/A in skim, 2%
and whole milk. It was shown that good recoveries were achived
when samples were spiked with as little as 312 pg/mL BoNT/A,
but that defatting by centrifugation (14,0006g, 15 min, 6uC) or a
10-fold dilution step was necessary to minimize sample interfer-
ence [12].
The assay described here for the detection of BoNT/B in milk
(skim, 2% and whole) does not require any defatting or dilution
step. Toxin was readily detectable at a concentration of 39 pg/mL
(3.9 pg by mass) in all three milk types, with recoveries of greater
than 80%. Although the human oral LD50 for BoNT/B has not
been determined, the estimated human oral LD50 for BoNT/A is
1 mg/kg body weight, or 70 mg for the average-sized human of
70 kg [26]. Assuming a similar toxicity for BoNT/B, the sandwich
ELISA can detect as little as ,1/1,800,000 of the LD50.
In summary, we have developed a sensitive assay specific for
BoNT/B that is both rapid and easy to use. This assay has the
potential to replace the use of the mouse bioassay given its much
greater sensitivity of detection. We are currently developing and
characterizing additional monoclonal antibodies to BoNT/B to
replace the polyclonal detector antibody used here. Our aim is to
develop an even more sensitive assay using multiple capture and
detector monoclonal antibodies and to explore their application in
lateral flow devices.
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